Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis (MYORHEIN)
Retrospective Evaluation of the Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis
Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. While ECRT techniques are commonly used in this situation, their actual effectiveness in eliminating myoglobin and improving renal function remains poorly established. In particular, mid-cut-off membranes, developed to better remove intermediate molecular weight molecules, could improve renal prognosis. This study aims to evaluate, using retrospective clinical data, the impact of these techniques on renal recovery.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nans FLORENS, MD
- Phone Number: 33 3 69 55 13 25
- Email: nans.florens@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Service de Néphrologie Dialyse Transplantation - CHU de Strasbourg - France
-
Contact:
- Nans FLORENS, MD
- Phone Number: 33 3 69 55 13 25
- Email: nans.florens@chru-strasbourg.fr
-
Principal Investigator:
- Nans FLORENS, MD
-
Sub-Investigator:
- Candice BARRIERE, MD
-
Sub-Investigator:
- Maxime INGWILLER, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult patient (≥18 years) with confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
Description
Inclusion Criteria:
- Adult patient (≥18 years).
- Patient is hospitalized in the nephrology or medical intensive care units of the Strasbourg University Hospitals (NHC or Hautepierre) between 2015 and 2024.
- Confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
- Patient has not objected to the reuse of their medical data.
Exclusion criteria:
- Patient has objected to the reuse of their data.
- Incomplete medical file preventing the complete analysis of the data necessary for the study.
- Subject under guardianship, curatorship, or legal protection.
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: RETROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total duration of dependence on extrarenal purification (ERP) (in days)
Time Frame: up to 15 month
|
Total duration of dependence on ERC (in days), defined as the number of days between initiation and discontinuation of any form of dialysis. |
up to 15 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9619
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.